comscoreEnhertu for HER2-Low Breast Cancer

Enhertu for HER2-Low Breast Cancer

Brian Wojciechowski, MD, explains what HER2-low breast is and the exciting results showing that Enhertu can help treat it.
Jul 8, 2022

At the recent 2022 American Society of Clinical Oncology Annual Meeting, researchers presented results showing Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki), which is a type of medicine doctors call an antibody-drug conjugate, improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.

Listen to the podcast to hear Dr. Wojciechowski explain:

  • what HER2-low breast cancer is

  • how Enhertu works

  • how the results of the DESTINY-Breast-04 study will change practice

Editor’s Note: On Aug. 5, 2022, the U.S. Food and Drug Administration (FDA) approved Enhertu to treat unresectable or metastatic HER2-low breast cancer in people who have previously received chemotherapy:

  • for metastatic disease

  • after surgery for early-stage disease that came back (recurred) within six months of completing chemotherapy

Unresectable means the cancer can’t be removed with surgery.

About the guest
Brian Wojciechowski headshot
Brian Wojciechowski, MD

Dr. Wojo is a medical oncologist outside of Philadelphia, PA, with Crozer Health. His research has been presented at the San Antonio Breast Cancer Symposium, and he is a speaker on medical ethics and the biology of cancer. Dr. Wojo sees cancer as a scientifically complex disease with psychological, social, and spiritual dimensions.

— Last updated on August 8, 2022, 9:24 PM

Support to produce more content like this

Your donation goes directly to what you read, hear, and see on